AISA Pharma Announces Positive Data Safety Monitoring Board Review of First Phase 2 Data of Profervia® to treat Raynaud’s Disease in Scleroderma Patients

Company to Move Forward with Key U.S. Regulatory Applications – Investigational New Drug and Orphan Drug Designation BOSTON, July 26, 2022 — Aisa Pharma, Inc. a privately-funded, clinical-stage biopharmaceutical company, today announced that the Data Safety Monitoring Board (DSMB) for the RECONNOITER Phase 2 study of Aisa’s Profervia® once-daily novel, oral calcium-channel antagonist has met …

AISA Pharma Announces Positive Data Safety Monitoring Board Review of First Phase 2 Data of Profervia® to treat Raynaud’s Disease in Scleroderma Patients Read More »

Aisa Pharma Starts Phase 2 Study of its proprietary drug for Raynauds and Scleroderma

AISA Pharma Announces Initiation of Patient Enrollment in Phase 2 Trial of Novel Therapy for Raynaud’s Disease in Scleroderma June 16, 2021 – Boston, MA : Aisa Pharma, Inc. a privately-funded, clinical-stage biopharmaceutical company, announces that it has begun enrolling patients in a Phase 2 study evaluating the novel investigational therapy Profervia® in patients with …

Aisa Pharma Starts Phase 2 Study of its proprietary drug for Raynauds and Scleroderma Read More »